National Institute for Healthcare and Excellence (NICE) recommend BRUKINSA (zanubturinib) for treatment of adult patients with marginal zone lymphoma who have received at least one prior anti-CD20-based therapy.
Natalia Elliot | August 6, 2024 | News story | Research and Development | BeiGene, National Institute of Healthcare and Excellence, Oncology, lymphoma, margina zone lymphoma, orphan disease
This week, BeiGene UK announced that BRUKINSA (zanubrutinib) has been recommended by the National Institute for Health and Care Excellence (NICE) for treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.
MLZ is considered to be an orphan disease, with an estimated incidence of 4.1 per 100,000 persons per year in the UK.
BRUKINSA is the first-ever treatment to be recommended by NICE for MZL, marking a significant milestone for BeiGene. In addition to treating MLZ, NICE has also recommended Brukinsa for routine use for Waldenstrom’s macroglobulinemia (WM) and eligble patients with chronic lymphocytic leukemia (CLL).
Marginal zone lymphoma (MZL) is a group of ultra-rare, slow growing B-cell malignancies that begin in the marginal zones of lymph tissue. Epidemiological data from Europe is limited, but the incidence rate of MZL is estimated to range between 20 and 30 persons per million per year. There are three different subtypes of MZL: extranodal marginal zone B-cell lymphoma, or mucosa-associated lymphoid tissue (MALT), which is most common; nodal marginal zone B-cell lymphoma which develops in the lymph nodes and is rare; and splenic marginal zone B-cell lymphoma which develops in the spleen, bone marrow, or both, and is the rarest form of the disease.
Related Content
Genmab to submit FDA application for lymphoma therapy
Global biotechnology company Genmab plans to submit a supplemental Biologics License Application (sBLA) to the …
AstraZeneca shares positive interim results from phase 3 lymphoma trial
AstraZeneca has announced positive high-level results from an interim analysis of the ECHO phase 3 …
Genentech’s Columbi meets primary endpoint in phase 3 trial for lymphoma treatment
Genentech, part of the Roche Group, has announced that its phase 3 STARGLO trial has …
